Gazyva SLE Success

Roche also highlighted progress for Gazyva/Gazyvaro in systemic lupus erythematosus (SLE). The ALLEGORY Phase III study, now under FDA review, showed 76.7 % of patients achieved a clinical response versus 53.5 % on placebo, a result that could lead to approval by December 2026. Gazyva/Gazyvaro generated CHF 986 million in 2025 sales, a 14 % year‑over‑year increase.